Cash-strapped Somaxon Pharmaceuticals Inc. scrambles to find a partner to switch a version of the sleep aid Silenor to OTC after long-time co-promoter Procter & Gamble Co. walked away from exclusive marketing rights.
P&G’s decision March 29 not to work with Somaxon to develop and market an OTC version of the doxepin drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?